AlphAIAlphAI — Financial news for AI agents
pharmatimes.comSEP 152 min read$JNJ

NICE backs daratumumab quadruplet for transplant‑eligible myeloma

NICE recommended daratumumab quadruplet for transplant-eligible myeloma patients. Johnson & Johnson's therapy showed 58% reduced risk of disease progression or death. NICE endorsed MRD-guided treatment. PERSEUS data showed a hazard ratio of 0.42 for progression-free survival at 47.5 months.

Original reporting
pharmatimes.com
Published Sep 15, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 1:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
NICE backs daratumumab quadruplet for transplant‑eligible myeloma — source image
Source · pharmatimes.com
Decision brief

The 30-second read

$JNJBullishHigh
01

Why it matters

The decision creates a new approved indication for J&J's drug, likely increasing sales and supporting the company's oncology growth narrative.

02

Market read

Regulatory approval in a major market can drive share price and set a precedent for other regions.

03

What to watch

Potential competition from biosimilars and pricing pressures could offset the benefit.

Relevance 8/10Novelty 8/10Timing: immediate

Background

NICE (UK's health technology assessment body) final draft guidance endorses a daratumumab‑based regimen for transplant‑eligible multiple myeloma patients.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

NICE issued guidance approving J&J's daratumumab‑based quadruplet for first‑line myeloma treatment in the UK.

Expected impact

Modest upside as UK sales lift revenue outlook.

Evidence & confidence

Regulatory endorsement in a major market adds a new revenue stream and validates clinical data, supporting a bullish view.

Market effects

Sector

Strengthens the oncology/biotech segment as a whole, highlighting the value of antibody‑drug combos.

Regional

UK and broader European markets may see increased demand for J&J oncology products.

Global

Adds to global confidence in J&J's pipeline, potentially influencing investor sentiment worldwide.

Counterpoint

What could challenge this read

UK guidance may not translate to US reimbursement, limiting revenue upside.

Key entities

  • Company
    Johnson & Johnson

    Manufacturer of daratumumab.

  • Regulatory Body
    NICE

    UK health technology assessment agency.

Read at source← All news

Related articles

SEP 15
$JNJMedAI 9/10

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026

Johnson & Johnson (JNJ) presented Phase 2b COPERNICUS study results at WCLC 2026, showing low rates of treatment-related events for RYBREVANT FASPRO (amivantamab) plus LAZCLUZE (lazertinib) in advanced NSCLC. Fewer than 1% of patients discontinued treatment at one year. The study supports the regimen's safety and tolerability, building on prior survival benefits.

prnewswire.com2 min
SEP 14
$JNJHighAI 9/10

JNJ Looks 37.8% Overvalued on GF Value™ as Dividend Sustainabili

Johnson & Johnson (JNJ) announced that its experimental treatment JNJ-5120/PIPE-307 failed to meet the primary endpoint in a phase 2 trial for major depressive disorder. The company's dividend yield is 1.95% with a payout ratio of 50% and a 3-year growth rate of 4.9%. JNJ's stock is trading 37.8% above its intrinsic GF Value™ of $193.33, with a GF Score™ of 83/100. Insiders have sold $154.9 million in shares over the past year.

gurufocus.com3 min
SEP 14
$JNJHighAI 9/10

J&J explores $20B DePuy Synthes sale to Apollo

Johnson & Johnson (JNJ) is in talks to sell its DePuy Synthes orthopedics unit to Apollo Global Management for $20B. DePuy Synthes generated $9.3B in sales last year. The deal, if finalized, would be Apollo's largest healthcare investment. JNJ is also considering other separation options, including a spin-off, to maximize shareholder value.

grafa.com2 min
SEP 14
$JNJHighAI 9/10

J&J in talks to sell DePuy Synthes to Apollo for $20 billion

Johnson & Johnson (JNJ) is in talks to sell its orthopedics unit, DePuy Synthes, to Apollo Global Management for approximately $20 billion. The unit generated $9.3 billion in sales last year. J&J may also consider spinning off the business as a standalone company. J&J's second-quarter sales were $25.31 billion, with the MedTech unit, including DePuy Synthes, recording $8.93 billion in sales.

yahoo.com2 min
SEP 14
$JNJHighAI 9/10

Amivantamab regimen delivers longest survival in EGFR Ex20ins lung cancer

Johnson & Johnson reported final results from the PAPILLON study, showing its amivantamab-based regimen achieved a median overall survival of 34.3 months in EGFR Ex20ins lung cancer patients, compared to 27.9 months for chemotherapy alone. The findings were presented at the IASLC 2026 World Conference on Lung Cancer. According to the company, the regimen demonstrated durability and value as a first-line treatment. The safety profile was consistent with earlier studies.

pharmatimes.com2 min